Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells
- PMID: 11590434
- DOI: 10.1038/nm1001-1118
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells
Abstract
Despite the existence of tumor-specific antigens and demonstrated presence of tumor-specific immune cells, the majority of tumors manage to avoid immune-mediated destruction. Various mechanisms have been suggested for tumor evasion from immune response. One such mechanism is thought to be mediated by transforming growth factor-beta (TGF-beta), an immunosuppressive cytokine found at the site of most tumors. We demonstrate here that T-cell-specific blockade of TGF-beta signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells. In addition, we provide mechanisms through which abrogation of TGF-beta signaling leads to the enhancement of anti-tumor immunity. Our data indicate that T-cell-specific blockade of TGF-beta signaling has strong therapeutic potential to shift the balance of the immune response in favor of anti-tumor immunity.
Similar articles
-
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.Clin Cancer Res. 2004 Sep 1;10(17):5907-18. doi: 10.1158/1078-0432.CCR-03-0611. Clin Cancer Res. 2004. PMID: 15355924
-
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.Cancer Res. 2005 Mar 1;65(5):1761-9. doi: 10.1158/0008-5472.CAN-04-3169. Cancer Res. 2005. PMID: 15753372
-
[Better tumor eradication in transgenic altered T-lymphocytes. Role of the TGF-beta signal transduction cascade].Hautarzt. 2001 Dec;52(12):1135-6. Hautarzt. 2001. PMID: 11910867 German. No abstract available.
-
Role of TGF-beta in immune-evasion of cancer.Microsc Res Tech. 2001 Feb 15;52(4):387-95. doi: 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W. Microsc Res Tech. 2001. PMID: 11170297 Review.
-
TGF-β: guardian of T cell function.J Immunol. 2013 Oct 15;191(8):3973-9. doi: 10.4049/jimmunol.1301843. J Immunol. 2013. PMID: 24098055 Free PMC article. Review.
Cited by
-
CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.J Gastrointest Cancer. 2021 Mar;52(1):1-10. doi: 10.1007/s12029-020-00457-1. J Gastrointest Cancer. 2021. PMID: 32700185 Review.
-
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14. J Immunol. 2012. PMID: 22984076 Free PMC article.
-
TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.J Leukoc Biol. 2015 Nov;98(5):703-12. doi: 10.1189/jlb.2HIMA1214-578R. Epub 2015 Jul 7. J Leukoc Biol. 2015. PMID: 26153417 Free PMC article.
-
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Arch Immunol Ther Exp (Warsz). 2010 Oct;58(5):335-46. doi: 10.1007/s00005-010-0090-1. Epub 2010 Aug 1. Arch Immunol Ther Exp (Warsz). 2010. PMID: 20680493 Free PMC article. Review.
-
Trends in cancer immunotherapy.Clin Med Insights Oncol. 2010 Jul 14;4:67-80. doi: 10.4137/cmo.s4795. Clin Med Insights Oncol. 2010. PMID: 20703326 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases